Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease DOI Creative Commons
Heike E. F. Becker, Karlijn Demers, Luc J. J. Derijks

et al.

Frontiers in Microbiology, Journal Year: 2023, Volume and Issue: 14

Published: Feb. 23, 2023

Background Inflammatory bowel disease (IBD) is a chronic relapsing-remitting disease. An adverse immune reaction toward the intestinal microbiota involved in pathophysiology and microbial perturbations are associated with IBD general flares specifically. Although medical drugs cornerstone of current treatment, responses vary widely between patients drugs. The can metabolize drugs, which may influence drug (non-)response side effects. Conversely, several impact thereby host This review provides comprehensive overview evidence on bidirectional interactions relevant (pharmacomicrobiomics). Methods Electronic literature searches were conducted PubMed, Web Science Cochrane databases to identify publications. Studies reporting composition and/or metabolism included. Results both enzymatically activate pro-drugs (e.g., case thiopurines), but also inactivate certain mesalazine by acetylation via N-acetyltransferase 1 infliximab IgG-degrading enzymes). Aminosalicylates, corticosteroids, thiopurines, calcineurin inhibitors, anti-tumor necrosis factor biologicals tofacitinib all reported alter composition, including changes diversity relative abundances various taxa. Conclusion Various lines have shown ability interfere vice versa. These treatment response, well-designed clinical studies combined vivo ex models needed achieve consistent findings evaluate relevance.

Language: Английский

The enteric nervous system relays psychological stress to intestinal inflammation DOI Creative Commons
Kai Markus Schneider, Niklas Blank, Yelina Alvarez

et al.

Cell, Journal Year: 2023, Volume and Issue: 186(13), P. 2823 - 2838.e20

Published: May 25, 2023

Language: Английский

Citations

154
Versatile carbon dots with superoxide dismutase-like nanozyme activity and red fluorescence for inflammatory bowel disease therapeutics DOI

Yana Ma,

Jingjie Zhao, Liangliang Cheng

et al.

Carbon, Journal Year: 2023, Volume and Issue: 204, P. 526 - 537

Published: Jan. 6, 2023

Language: Английский

Citations

71
IBD disease-modifying therapies: insights from emerging therapeutics DOI
Niranjan G. Kotla, Yury Rochev

Trends in Molecular Medicine, Journal Year: 2023, Volume and Issue: 29(3), P. 241 - 253

Published: Jan. 30, 2023

Language: Английский

Citations

64
Galactooligosaccharides and Limosilactobacillus reuteri synergistically alleviate gut inflammation and barrier dysfunction by enriching Bacteroides acidifaciens for pentadecanoic acid biosynthesis DOI Creative Commons
Yujun Wu, Xiangyu Zhang, Xiaoyi Liu

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Oct. 28, 2024

Ulcerative colitis (UC) is a debilitating inflammatory bowel disease characterized by intestinal inflammation, barrier dysfunction, and dysbiosis, with limited treatment options available. This study systematically investigates the therapeutic potential of synbiotic composed galactooligosaccharides (GOS) Limosilactobacillus reuteri in murine model colitis, revealing that GOS L. synergistically protect against inflammation dysfunction promoting synthesis pentadecanoic acid, an odd-chain fatty from Bacteroides acidifaciens. Notably, synbiotic, B. acidifaciens, acid are each capable suppressing enhancing tight junction inhibiting NF-κB activation. Furthermore, similar reduction acidifaciens levels also observed feces both human UC patients lipopolysaccharide-induced pigs. Our findings elucidate protective mechanism highlight its potential, along for other disorders. Here, Yujun Wu colleagues report alleviates gut animals enriching showing treating ulcerative colitis.

Language: Английский

Citations

17
Understanding the therapeutic toolkit for inflammatory bowel disease DOI
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

Language: Английский

Citations

4
Function and inhibition of P38 MAP kinase signaling: Targeting multiple inflammation diseases DOI
Jiahui Wang, Yongjian Liu,

Yushi Guo

et al.

Biochemical Pharmacology, Journal Year: 2023, Volume and Issue: 220, P. 115973 - 115973

Published: Dec. 14, 2023

Language: Английский

Citations

35
Recent updates on correlation between reactive oxygen species and synbiotics for effective management of ulcerative colitis DOI Creative Commons
Sumel Ashique, Neeraj Mishra, Ashish Garg

et al.

Frontiers in Nutrition, Journal Year: 2023, Volume and Issue: 10

Published: July 20, 2023

Ulcerative colitis (UC) is presently considered a multifactorial pathology, which may lead to persistent inflammatory action of the gastrointestinal tract (GIT) because an improperly managed immunological reactivity intestinal microbiota found in GIT. The immune response common commensal microbes plays essential role inflammation related UC synbiotics, and it important element optimal therapy UC. Therefore, i.e., mixture prebiotics probiotics, help control diseased state. Synbiotics alleviate colon by lowering reactive oxygen species (ROS) improving level antioxidant enzymes such as catalase (CAT), glutathione peroxidase (GPX), superoxide dismutase (SOD). Prebiotic supplementation not practice at moment, despite numerous research findings proving that benefits both probiotics encourage their continued existence positioning GIT, with positive effects on human health managing response. However, fact there have been fewer studies treatment different coupled selected prebiotics, outcomes these very favorable. This evidence-based study explores possible ROS, SOD, synbiotics proposed review also focuses alteration gut microbiota, defense tract, management Thus, current article emphasizes oxidative stress signaling GI stress-based pathomechanisms patients, therapies inhibiting stress’ effects.

Language: Английский

Citations

31
Glucocorticoids, their uses, sexual dimorphisms, and diseases: new concepts, mechanisms, and discoveries DOI
Genesee J. Martinez,

Malik Appleton,

Zachary A. Kipp

et al.

Physiological Reviews, Journal Year: 2023, Volume and Issue: 104(1), P. 473 - 532

Published: Sept. 21, 2023

The normal stress response in humans is governed by the hypothalamic-pituitary-adrenal (HPA) axis through heightened mechanisms during stress, raising blood levels of glucocorticoid hormone cortisol. Glucocorticoids are quintessential compounds that balance proper functioning numerous systems mammalian body. They also generated synthetically and preeminent therapy for inflammatory diseases. act binding to nuclear receptor transcription factor (GR), which has two main isoforms (GRα GRβ). Our classical understanding signaling from GRα isoform, binds hormone, whereas GRβ no known ligands. With glucocorticoids being involved many physiological cellular processes, even small disruptions their release via HPA axis, or changes GR isoform expression, can have dire ramifications on health. Long-term chronic lead a glucocorticoid-resistant state, we deliberate how this impacts disease treatment. Chronic treatment noticeable side effects such as weight gain, adiposity, diabetes, others discuss detail. There sexually dimorphic responses glucocorticoids, women tend more hyperresponsive than men. This review summarizes our critically analyzes beneficial deleterious sexual differences cause dichotomy responses. We future propose new concept dual agonist postulate why activating both may prevent resistance.

Language: Английский

Citations

29
Manipulating Microbiota in Inflammatory Bowel Disease Treatment: Clinical and Natural Product Interventions Explored DOI Open Access

Mengjie Zhu,

Yijie Song, Yu Xu

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(13), P. 11004 - 11004

Published: July 2, 2023

Inflammatory bowel disease (IBD) is a complex multifactorial chronic inflammatory disease, that includes Crohn's (CD) and ulcerative colitis (UC), having progressively increasing global incidence. Disturbed intestinal flora has been highlighted as an important feature of IBD offers promising strategies for remedies. A brief overview the variations occurring in during presented, role gut microbiota barrier maintenance, immune metabolic regulation, absorption supply nutrients reviewed. More importantly, we review drug research on past ten years, including clinical natural drugs, well adjuvant therapies, such Fecal Microbiota Transplantation probiotic supplements. We also summarize interventions mechanisms these drugs microbiota.

Language: Английский

Citations

26
Pathological mechanism and targeted drugs of ulcerative colitis: A review DOI Creative Commons
Meitong Guo, Xiaoyan Wang

Medicine, Journal Year: 2023, Volume and Issue: 102(37), P. e35020 - e35020

Published: Sept. 15, 2023

Ulcerative colitis (UC) is a chronic inflammatory disease of the colon with abdominal pain, diarrhea, and mucopurulent stools as main symptoms. Its incidence increasing worldwide, traditional treatments have problems such immunosuppression metabolic disorders. In this article, etiology pathogenesis ulcerative are reviewed to clarify targeted drugs UC in latest research. Our aim provide more ideas for clinical treatment new drug development UC, mainly by analyzing sorting out relevant literature on PubMed, summarizing finding that it related genetic, environmental, immune other factors, explaining its from NF-κB pathway, PI3K/Akt signaling JAK/STAT obtaining anti-TNF-α monoclonal antibodies, integrin antagonists, IL-12/IL-23 novel UC-targeted JAK inhibitors SIP receptor agonists. We believe rational selection formulation best dosing strategy under comprehensive consideration evaluation way treat UC.

Language: Английский

Citations

26